PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors

Summary

HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth. This study is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10241 at single dose and multiple doses.

Timeline

Start

2019-06-21

Primary completion

2020-12-31

Completion

2021-12-31

Drugs

Indications